Gemcabene is under clinical development by NeuroBo Pharmaceuticals and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to GlobalData, Phase II drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gemcabene’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gemcabene overview
Gemcabene calcium is under development for the treatment of osteoarthritis, hypertension, homozygous familial hypercholesterolemia (HoFH), heterozygous familial hypercholesterolemia (HeFH, non-alcoholic steatohepatitis, non alcoholic fatty liver disease, and non-familial hypercholesterolemia in ASCVD patients. The therapeutic candidate is administered through oral route. It regulates the lipid level. It was also under development for the treatment of mixed dyslipidemia and hypertriglyceridemia.
It was under development for the treatment of familial chylomicronemia sndrome (FCS), familial partial lipodystrophy (FPL) disease and acute COVID-19 indication caused by SAR-COV-2.
NeuroBo Pharmaceuticals overview
NeuroBo Pharmaceuticals (NeuroBo), a subsidiary of Dong-A ST Co Ltd, is a biotechnology company. It develops innovative drugs for cardiometabolic diseases. The company’s product pipeline includes DA-1241, a once-daily oral G-protein-coupled receptor 119 (GPR119) agonist currently in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and DA-1726, a novel dual oxyntomodulin (OXM) analog designed for once-a-week injection that acts as an agonist for both the glucagon-like peptide-1 receptor (GLP1R) and the glucagon receptor (GCGR). It is also evaluating ANA001, an oral niclosamide formulation for moderate COVID-19; NB-01 for painful diabetic neuropathy (PDN); NB-02, which targets cognitive impairment; and Gemcabene, aimed at treating dyslipidemia. NeuroBo is headquartered in Boston, Massachusetts, the US.
For a complete picture of Gemcabene’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
